# The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease

> **NCT01268241** · — · COMPLETED · sponsor: **CENTOGENE GmbH Rostock** · enrollment: 200 (actual)

## Conditions studied

- Fabry Disease
- Fabry´s Disease
- Anderson-Fabry Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01268241
- **Lead sponsor:** CENTOGENE GmbH Rostock
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268241, "The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01268241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*